🏛️ Verified NIH Record • Updated 2026-04-29
Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation (NCT05509933)
🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Henry Ford Health System
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.
Who can join: Review the eligibility criteria below.
Location: Henry Ford Health System — Detroit, Michigan
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Henry Ford Health System — Detroit, Michigan
📞 Contact the Study Coordinator
Phone: (313) 713-3910
Email: sfarhan1@hfhs.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Engraftment Syndrome clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.